Amrubicin as second-line treatment for small-cell lung cancer: a Meta-analysis

JIN Haichao; XING Fangkai; CHEN Tao; LV Wenling

doi:10.3969/j.issn.1006-0111.2017.01.021

Message Board

Respected readers, authors and reviewers, you can add comments to this page on any questions about the contribution, review, editing and publication of this journal. We will give you an answer as soon as possible. Thank you for your support!

Name

E-mail

Phone

Title

Content

Verification Code

Objective To evaluate the efficacy and safety of amrubicin for small-cell lung cancer(SCLC). Methods PubMed, Embase, the Cochrane Library and CNKI were searched to collect amrubicin data in the treatment of SCLC. A Meta-analysis was performed over the published clinical trials. The efficacy and safety of amrubicin were evaluated based on overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and toxicity. Results Our analysis for 6 clinical trials indicated that amrubicin had significantly higher ORR than control group[RR 1.72,95% CI (1.39, 2.14),P=0.000], the OS, PFS and toxicity were no-inferior to the control group(P=0.405,P=0.456). Conclusion Amrubicin can be considered as a good second-line treatment for relapsed SCLC.

Amrubicin as second-line treatment for small-cell lung cancer: a Meta-analysis

1. The 71571 Unit of PLA, Yantai 265500, China

2. The Gynecology & Obstetrics of Yuhuangding Hospital, Yantai 265000, China

Received Date: 2016-03-07

Rev Recd Date: 2016-07-18

Key words:

Abstract: Objective To evaluate the efficacy and safety of amrubicin for small-cell lung cancer(SCLC). Methods PubMed, Embase, the Cochrane Library and CNKI were searched to collect amrubicin data in the treatment of SCLC. A Meta-analysis was performed over the published clinical trials. The efficacy and safety of amrubicin were evaluated based on overall survival (OS), progression-free survival (PFS), overall response rate (ORR) and toxicity. Results Our analysis for 6 clinical trials indicated that amrubicin had significantly higher ORR than control group[RR 1.72,95% CI (1.39, 2.14),P=0.000], the OS, PFS and toxicity were no-inferior to the control group(P=0.405,P=0.456). Conclusion Amrubicin can be considered as a good second-line treatment for relapsed SCLC.

HTML

Reference (13)

[1]	Cheng S, Evans WK, Stys-Norman D, et al. Chemotherapy for relapsed small cell lung cancer:a systematic review and practice guideline[J]. J Thorac Oncol, 2007,2(4):348-354.
[2]	Kim YH, Mishima M. Second-line chemotherapy for small-cell lung cancer (SCLC)[J]. Cancer Treat Rev, 2011,37(2):143-150.
[3]	Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology:a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group[J]. JAMA, 2000,283(15):2008-2012.
[4]	Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses[J]. Eur J Epidemiol, 2010,25(9):603-605.
[5]	O'Brien ME, Konopa K, Lorigan P, et al. Randomised phase Ⅱ study of amrubicin as single agent or in combination with cisplatin versus cisplatin etoposide as first-line treatment in patients with extensive stage small cell lung cancer-EORTC 08062[J]. Eur J Cancer, 2011,47(15):2322-2330.
[6]	Satouchi M, Kotani Y, Shibata T, et al. Phase Ⅲ study comparing amrubicin plus cisplatin with irinotecan plus cisplatin in the treatment of extensive-disease small-cell lung cancer:JCOG 0509[J]. J Clin Oncol, 2014,32(12):1262-1268.
[7]	Sekine I, Okamoto H, Horai T, et al. A randomized phase Ⅲ study of single-agent amrubicin vs. carboplatin/etoposide in elderly patients with extensive-disease small-cell lung cancer[J]. Clin Lung Cancer, 2014,15(2):96-102.
[8]	Wakuda K, Kenmotsu H, Naito T, et al. Efficacy of rechallenge chemotherapy in patients with sensitive relapsed small cell lung cancer[J]. Am J Clin Oncol, 2015,38(1):28-32.
[9]	Inoue A, Sugawara S, Yamazaki K, et al. Randomized phase Ⅱ trial comparing amrubicin with topotecan in patients with previously treated small-cell lung cancer:North Japan Lung Cancer Study Group Trial 0402[J]. J Clin Oncol, 2008,26(33):5401-5406.
[10]	Inoue A, Sugawara S, Maemondo M, et al. Randomized phase Ⅱ trial comparing amrubicin with re-challenge of platinum doublet in patients with sensitive-relapsed small-cell lung cancer:North Japan Lung Cancer Study Group trial 0702[J]. Lung Cancer, 2015, 89(1):61-65.
[11]	Jotte R, Conkling P, Reynolds C, et al. Randomized phase Ⅱ trial of single-agent amrubicin or topotecan as second-line treatment in patients with small-cell lung cancer sensitive to first-line platinum-based chemotherapy[J]. J Clin Oncol, 2011,29(3):287-293.
[12]	von Pawel J, Jotte R, Spigel DR, et al. Randomized phase Ⅲ trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer[J]. J Clin Oncol, 2014,32(35):4012-4019.
[13]	Tani N, Yabuki M, Komuro S, et al. Characterization of the enzymes involved in the in vitro metabolism of amrubicin hydrochloride[J]. Xenobiotica, 2005,35(12):1121-1133.

Message Board

Amrubicin as second-line treatment for small-cell lung cancer: a Meta-analysis

doi: 10.3969/j.issn.1006-0111.2017.01.021

Abstract

References

Proportional views

通讯作者: 陈斌, bchen63@163.com

Article Metrics

Related

Proportional views